Sab biotherapeutics announces publication of nonclinical data demonstrating sab-185 has high potency for effectively neutralizing circulating and emerging sars-cov-2 variants

In the fda-conducted study, sab-185 consistently demonstrated high avidity and high potency for effectively neutralizing a broad range of sars-cov-2 strains and variants through delta

SABS Ratings Summary

SABS Quant Ranking